Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue Contre le Cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France; Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33006, Oviedo, Spain.
Trends Endocrinol Metab. 2021 May;32(5):264-294. doi: 10.1016/j.tem.2021.02.005. Epub 2021 Mar 8.
Human obesity is accompanied by alterations in the blood concentrations of multiple circulating appetite regulators. Paradoxically, most of the appetite-inhibitory hormones are elevated in nonsyndromic obesity, while most of the appetite stimulatory hormones are reduced, perhaps reflecting vain attempts of regulation by inefficient feedback circuitries. In this context, it is important to understand which appetite regulators exhibit a convergent rather than paradoxical behavior and hence are likely to contribute to the maintenance of the obese state. Pharmacological interventions in obesity should preferentially consist of the supplementation of deficient appetite inhibitors or the neutralization of excessive appetite stimulators. Here, we critically analyze the current literature on appetite-regulatory peptide hormones. We propose a short-list of appetite modulators that may constitute the best candidates for therapeutic interventions.
人类肥胖伴随着多种循环食欲调节剂血液浓度的改变。矛盾的是，大多数抑制食欲的激素在非综合征性肥胖中升高，而大多数刺激食欲的激素降低，这可能反映了无效反馈回路的无效调节的徒劳尝试。在这种情况下，重要的是要了解哪些食欲调节剂表现出趋同而不是矛盾的行为，因此可能有助于维持肥胖状态。肥胖的药物干预应优先包括缺乏食欲抑制剂的补充或对过量食欲刺激物的中和。在这里，我们批判性地分析了关于食欲调节肽激素的当前文献。我们提出了一个可能成为治疗干预最佳候选物的食欲调节剂的简短清单。
